Deferred Income Tax Expense (Benefit) of ENZON PHARMACEUTICALS, INC. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary: ENZON PHARMACEUTICALS, INC. quarterly and annual Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
ENZON PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $16,000, a 68% decline year-over-year.
ENZON PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was $364,000.
ENZON PHARMACEUTICALS, INC. annual Deferred Income Tax Expense (Benefit) for 2024 was $342,000.
ENZON PHARMACEUTICALS, INC. annual Deferred Income Tax Expense (Benefit) for 2023 was $157,000, a 22% increase from 2022.
ENZON PHARMACEUTICALS, INC. annual Deferred Income Tax Expense (Benefit) for 2022 was $202,000.
Source SEC data: View on sec.gov

Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)

Deferred Income Tax Expense (Benefit), Quarterly (USD)

Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

Deferred Income Tax Expense (Benefit), Annual (USD)

Deferred Income Tax Expense (Benefit), YoY Annual Change (%)

ENZON PHARMACEUTICALS, INC. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$364,000	$16,000	-$34,000	-68%	01 Jul 2025	30 Sep 2025	10-Q	12 Nov 2025	2025	Q3
Q2 2025	$398,000	$42,000	+$38,000	+950%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2025	Q2
Q1 2025	$360,000	$17,000	+$18,000		01 Jan 2025	31 Mar 2025	10-Q	09 May 2025	2025	Q1
Q4 2024	$342,000	$289,000	+$537,000		01 Oct 2024	31 Dec 2024	10-K	21 Feb 2025	2024	FY
Q3 2024	$195,000	$50,000	-$26,000	-34%	01 Jul 2024	30 Sep 2024	10-Q	12 Nov 2025	2025	Q3
Q2 2024	$169,000	$4,000	-$47,000	-92%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2025	Q2
Q1 2024	$122,000	$1,000	+$35,000	+97%	01 Jan 2024	31 Mar 2024	10-Q	09 May 2025	2025	Q1
Q4 2023	$157,000	$248,000			01 Oct 2023	31 Dec 2023	10-K	21 Feb 2025	2024	FY
Q3 2023		$76,000			01 Jul 2023	30 Sep 2023	10-Q	05 Nov 2024	2024	Q3
Q2 2023		$51,000			01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023		$36,000			01 Jan 2023	31 Mar 2023	10-Q	10 May 2024	2024	Q1
Q1 2018		$0	-$424,000	-100%	01 Jan 2018	31 Mar 2018	10-Q	10 May 2018	2018	Q1
Q1 2017		$424,000	-$604,000	-59%	01 Jan 2017	31 Mar 2017	10-Q	10 May 2018	2018	Q1
Q1 2016		$1,028,000	+$3,526,000		01 Jan 2016	31 Mar 2016	10-Q	11 May 2017	2017	Q1
Q1 2015		$2,498,000	-$2,498,000		01 Jan 2015	31 Mar 2015	10-Q	09 May 2016	2016	Q1
Q1 2014		$0			01 Jan 2014	31 Mar 2014	10-Q	13 May 2015	2015	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$342,000	+$499,000		01 Jan 2024	31 Dec 2024	10-K	21 Feb 2025	2024	FY
2023	$157,000	+$45,000	+22%	01 Jan 2023	31 Dec 2023	10-K	21 Feb 2025	2024	FY
2022	$202,000			01 Jan 2022	31 Dec 2022	10-K	20 Mar 2024	2023	FY
2018	$0	-$3,362,000	-100%	01 Jan 2018	31 Dec 2018	10-K	21 Feb 2019	2018	FY
2017	$3,362,000	-$4,387,000	-57%	01 Jan 2017	31 Dec 2017	10-K	21 Feb 2019	2018	FY
2016	$7,749,000	+$18,860,000		01 Jan 2016	31 Dec 2016	10-K	21 Mar 2018	2017	FY
2015	$11,111,000	-$11,111,000		01 Jan 2015	31 Dec 2015	10-K	24 Mar 2017	2016	FY
2014	$0			01 Jan 2014	31 Dec 2014	10-K	21 Mar 2016	2015	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.